- Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines
- Two companies pledge to make joint effort to raise awareness of mental health issues as part of the “We Care About Mental Health” initia✅tive
Luye Pharma and Distriphil sign partnership agreement
(From left to right: Dr. Yehong Zhang, President of Luye Pharma (International); Mr. William Chiongbian II, Founder & President of Distriphil)
Luye Pharma and Distriphil launch the “We Care About Mental Health” initiative in the Philippines
(From left to right: Mr. Andy Siow, APAC Regional Director of Luye Pharma (International); Mr. Michael Quijano, Vice President & Chief Operation Officer of Distriphil)
About Seroquel® and Seroquel XR®
Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) are atypical anti-psychotic (AAP) medicines with antidepressant properties. The main indications for Seroquel® are the treatment of schizophrenia and bipolar disorder. Seroquel XR® is also approved in some markets for major depressive disorder and generalized anxiety disorder.About Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Along with a number of new drugs and formulations in the central nervous system and oncology therapeutic areas currently under study in the U.S., Europe and Japan, Luye Pharma has reached high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems, as well as actively making strategic developments in the fields of biological antibodies, cell therapies and gene therapies, among others. Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets.About Distriphil
Distribution Solutions Phils., Inc.(Distriphil) is a national pharmaceutical company. It is under the banner of a holding company, MVC Corporation where subsidiaries are known to be the biggest provider of supply chain solutions in the Philippines, the Fast Logistics Corporation - Fast Services, Fast Distribution. Our business revolves around the marketing and distribution of our own in house products, as well as providing sales and/or marketing support, including warehousing and distribution services of pharmaceuticals, medical devices and nutritional supplements to other national or multinational pharmaceutical companies. Distriphil over the years has partnered and gained the trust of multinational companies including Roche, Merz Aesthetics, GSK Consumer Health, Cheplapharma of Germany and Edsel Healthcare of Hong Kong to promote their brands. To date we attribute a significant growth in fulfilling our vision of providing care and improving the health of every Filipino by providing access to quality medicines.